Explore every episode of the podcast DarshanTalks Podcast
| Title | Pub. Date | Duration | |
|---|---|---|---|
| Your Mood, Energy, and Sleep Claims Might Be Regulated | 11 Dec 2025 | 00:01:04 | |
A lot of brands start with harmless wellness promises like better mood, more energy, or improved sleep. As the business grows, though, marketing often becomes bolder, and that’s where risk creeps in. The FDA steps in when your claims imply treating or preventing a disease, which can flip your product into drug or device territory. The FTC expects every wellness claim to be truthful and supported by real evidence. In this episode, I explain how I review labels, websites, and social content, map each claim to the right regulatory bucket, and draft compliant alternatives that keep your marketing appealing without triggering expensive oversight. I also build claim checklists to help teams avoid drift in the future. Call, click, or email if you need support. www.kulkarnilawfirm.com | |||
| Device Fail: The Legal Anatomy of a Faulty Implant Scandal | 10 Dec 2025 | 00:04:58 | |
A knee implant meant to restore mobility. A surgeon secretly collecting international trips and consulting checks. A device company accused of selling a product they allegedly knew would fail. This episode breaks down the Aesculap case, the $38.5M settlement, and what it teaches us about kickbacks, forged FDA documents, and the catastrophic cost of weak compliance controls. If your team works in pharma, med-tech, or clinical research, you don’t want to miss this one. www.kulkarnilawfirm.com | |||
| Compliance guru talks practical Insights on Speaker Programs | 07 Nov 2025 | 00:13:11 | |
In this episode, host Darshan Kulkarni speaks with Joseph Keeney about speaker programs in the life sciences industry, exploring practical differences between small and large companies. They highlight that while fundamentals like compliance, pragmatism, and sound business principles apply across organizations, strong mitigating controls and adherence to legal and industry codes are critical. Joseph explains the importance of engaging with various business units to understand real plans, aligning training programs with compliance needs, and avoiding pitfalls that could trigger violations of federal anti-kickback statutes. He emphasizes careful management of speakers bureau rosters, evaluating the necessity and effectiveness of healthcare professionals (HCPs) on the program, and considering fair market value while avoiding indirect remuneration risks. The conversation also covers compensation approaches, proper documentation, and the value of third-party partners for benchmarking and compliance review. Joseph stresses that each program should be tailored to the company’s unique needs and highlights the importance of ongoing evaluation, diligence, and oversight. Reach out to learn more. www.kulkarnilawfirm.com | |||
| Future-Proof Sites: SOS Insights Revealed | 27 Mar 2025 | 00:08:38 | |
In this episode, Darshan Kulkarni sits down with Raymond Nomizu, founder and co-CEO of CRIO, to discuss key takeaways from the SOS conference and the evolving landscape of clinical research. Raymond shares his journey from running a clinical research site to founding CRIO, a platform designed to modernize site operations through eSource, CTMS, and real-time data solutions. They explore major industry trends, including the rise of site networks, increasing sponsor demand for real-time data access, and the shifting role of decentralized clinical trials (DCTs). They also discuss whether DCTs are truly revolutionizing research or simply becoming part of standard clinical operations. Raymond emphasizes that while centralization can improve efficiency in areas like finance, data management, and regulatory processes, the investigator-patient relationship must remain localized for research to be effective. The SOS conference highlighted these ongoing shifts, and the conversation dives into how sites can stay competitive by adapting to sponsor expectations, leveraging technology, and optimizing operations. www.kulkarnilawfirm.com | |||
| Why Food M&A Deals Collapse—And How to Prevent It | 25 Mar 2025 | 00:02:29 | |
Darshan talks about a major blind spot in food M&A—hidden compliance risks that can destroy a deal overnight. While most focus on financials, market share, and synergies, they fail to account for regulatory pitfalls that can trigger investigations, recalls, or severe penalties. Imagine being deep in negotiations, only to discover unapproved ingredients, misleading health claims, or an undisclosed FDA warning letter buried in company files. Some executives make the mistake of pushing forward, thinking they’ll fix it later—but regulators like the FDA, USDA, and FTC won’t wait. Many assume their internal legal teams can handle compliance due diligence, but food regulations are complex, spanning labeling, safety, advertising, and state consumer protection laws. The Kulkarni Law Firm specializes in identifying and resolving these risks before they become deal-breakers. We help buyers conduct regulatory due diligence, engage with federal and state regulators, assess liability risks in labeling and advertising, and structure compliance-driven transactions. If you're involved in food M&A, don’t let compliance issues turn your investment into a liability. Reach out to the Kulkarni Law Firm to protect your deal and ensure regulatory success. www.kulkarnilawfirm.com | |||
| Non-Compliance Led to QOL Medical's $47M Settlement | 23 Mar 2025 | 00:02:00 | |
The recent $47 million settlement involving QOL Medical and its CEO is a stark reminder of the consequences of crossing legal and ethical boundaries. Allegations of offering free Carbon 13 breath test kits as kickbacks to induce prescriptions for Sucraid, a treatment for congenital sucrose isomaltase deficiency (CSID), aren't just about non-compliance—they’re about patient safety. The breath tests could not specifically diagnose CSID but were marketed as such, leading to inappropriate prescriptions and fraudulent claims submitted to federal healthcare programs. This not only wasted resources but also put vulnerable patients at risk. For those in the rare disease treatment space, this case highlights the need for transparency and truth in marketing. Ask yourself: Are your promotional strategies truthful? Are you offering incentives that could be misconstrued as kickbacks? In a field with limited data and high stakes, misleading marketing can erode trust, tarnish reputations, and invite legal scrutiny. Compliance is not just a checkbox—it’s a commitment to ethical practices that prioritize patient well-being. As you navigate these challenges, ensure your marketing practices are compliant while effectively educating healthcare providers about rare disease treatments. QOL Medical’s costly misstep should serve as a warning. For guidance on staying compliant, reach out to the Kulkarni Law Firm and learn how we can help. www.kulkarnilawfirm.com | |||
| FDA Regulatory Submissions: Challenges, Trends, and Future Predictions | 21 Mar 2025 | 00:02:52 | |
Edye Edens from KLF offers a brief yet in-depth overview of FDA regulatory submissions for clinical research in the U.S., reflecting on both current practices and predictions for 2025. She highlights how AI tools and evolving political dynamics are shaping the regulatory landscape, emphasizing that while efficiency improvements are necessary, careful and strategic approaches are critical to maintain the FDA’s global reputation and safety standards. Edye discusses the complexity of submissions like Investigational New Drug (IND) and Investigational Device Exemption (IDE) applications, noting the significant preclinical work, detailed documentation, and thorough FDA review process involved. She also underscores the global weight of FDA approvals, as many international regulatory bodies rely on FDA assessments as a benchmark. Finally, Edye poses key questions to her audience:
Reach out for more info! www.kulkarnilawfirm.com | |||
| How to do a VR promo check - Carly Schaecter gives us her advice | 19 Mar 2025 | 00:14:42 | |
Carly Schaechter discusses the potential of VR in drug promotion and the challenges of reviewing VR content for the PRC. Key points include the need for VR expertise to conceptualize interactive, engaging content. Choosing VR over AR depends on the objectives, with VR offering more controlled environments. Ensuring user control, addressing misinformation, and learning from past mistakes are crucial for successful VR implementation. Gamification and user experience evaluation are critical elements of the review process.
www.kulkarnilawfirm.com | |||
| Diversity Matters in Clinical Trials | 18 Mar 2025 | 00:05:42 | |
In this insightful discussion, Shuja Naqvi, CEO of Biopharma Informatics, joins Darshan Kulkarni to explore the evolving landscape of clinical research. Shuja shares how his company has expanded across seven states, strategically choosing locations to promote diversity—not just in ethnicity, but also in socioeconomic and regional representation. He highlights the importance of gathering data from various populations to improve the effectiveness and inclusivity of clinical trials. They delve into the growing role of research as a care option, particularly for uninsured patients who, through clinical trial participation, gain access to free medical care, medications, and life-saving screenings. While this model presents clear benefits, it also raises ethical concerns, such as the potential for undue influence when patients rely on trials for necessary healthcare. Shuja emphasizes the role of informed consent and IRB oversight in ensuring that participation remains voluntary and ethical. The conversation also addresses compensation for trial participants. Shuja argues that current payments are insufficient, considering the risks involved in testing non-FDA-approved treatments. He stresses that researchers should ask themselves: “Would I enroll my own family in this trial?” If not, it’s a sign that ethical standards and participant compensation need to be reconsidered. www.kulkarnilawfirm.com | |||
| EMA’s LLM Guidelines Impact Life Sciences | 16 Mar 2025 | 00:02:44 | |
The EMA's new guiding principles on LLMs represent a transformative step in regulatory science, addressing both the immense potential and significant risks of these technologies. These principles emphasize the need to balance innovation with ethical considerations, tackling issues like data privacy, misinformation, and bias. LLMs, such as ChatGPT, hold promise for automating workflows like medical translations, pharmacovigilance reporting, and coding support. However, the EMA stresses continuous education, ethical governance, and collaboration among stakeholders to ensure responsible use. Key recommendations include adopting strategies like prompt engineering to optimize AI outputs and fostering collaboration through initiatives like the European Specialized Expert Community (ESEC) for AI knowledge sharing. Bite-sized, accessible training programs can also help demystify LLMs for teams. As the life sciences sector embraces these tools, organizations must align with these principles to ensure compliant and impactful AI integrations. The Kulkarni Law Firm offers expert advice for ethical AI deployment—don’t wait to make your AI strategy future-ready! www.kulkarnilawfirm.com | |||
| How to Network Like a Pro at Conferences | 12 Mar 2025 | 00:17:08 | |
In this episode, Darshan sits down with Brook White from CRIO to dive into the value of attending conferences and how to make the most of them. They met at a past conference and quickly realized how much we had to learn from each other, so I asked Brook to come on and share her insights. They start by discussing whether conferences are truly valuable—considering the costs, time investment, and potential for networking. While online learning can be beneficial, conferences offer unique opportunities for interaction and relationship-building, which can lead to new clients, partnerships, and ideas. Brooke emphasizes the importance of setting clear goals before attending a conference, whether it's for lead generation, education, or brand awareness. They also talk about market segmentation and how CRIO approaches conferences with a targeted strategy, dividing attendees into categories like existing clients, partners, and prospective future clients. This helps the team prioritize and engage with the right people, even before the conference begins. Brooke shares her process of reaching out to these groups and how CRIO maximizes their time at events. Finally, they touch on the importance of building relationships at conferences—whether you're engaging with potential partners, clients, or learning from industry leaders. And while swag might seem trivial, Brooke explains that it's more about creating brand recognition and offering an opportunity to engage with attendees. If you're heading into conference season, this conversation is packed with valuable tips to help you navigate the event landscape more effectively. #SOSconference2025 #SaveOurSites2025 #clinicaltrials #clinicalresearch #clinicaltrialcompliance #clinicaltrialmanagement #FDACompliance #darshantalks #dt #kulkarnilawfirm #klf www.kulkarnilawfirm.com | |||
| Getting Ready for SOS 2025: FDA 483s, SOPs, and Site Survival | 10 Mar 2025 | 00:10:35 | |
In this conversation, Edye Edens and Darshan Kulkarni discuss the excitement and plans for the upcoming Save Our Sites (SOS) Second Annual Conference in Oklahoma City. They highlight the importance of connecting with key industry leaders and peers in person, including names like Dan Sfera, Brad Hightower, and others who have been instrumental voices in the clinical research space. Darshan shares that Kulkarni Law Firm (KLF) will be participating and is excited to engage with attendees, talk about their offerings, and provide exclusive giveaways related to compliance and FDA inspections. Darshan emphasizes that KLF will focus on how to prevent and respond to FDA 483s, covering topics like audit readiness, proper handling of inspections, and how to de-escalate findings before they escalate into warning letters. He also underscores the importance of understanding the inspection process, including the fact that "it's a negotiation until the report is issued," and the role of policies, procedures, and professional conduct during audits. Edye highlights her session on SOPs (Standard Operating Procedures), where she will speak alongside Jen Pages, Scott Wit, and Brad Hightower (moderator). Their panel will cover critical topics like:
They aim to address real-life issues sites face, including how to tailor or adapt SOP templates and how to leverage them to prevent issues with sponsors and regulators. A surprise giveaway will also be available for those who attend the session. Both Edye and Darshan emphasize that SOS is about community supporting community, not just traditional presentations. The goal is to share actionable, free value, foster real conversations about clinical site challenges, and help each other grow in the clinical research space. They also playfully joke about friendly competition on session attendance, adding a light-hearted tone to the conversation. In summary, attendees can expect:
Stay tuned for more updates. www.kulkarnilawfirm.com | |||
| Maximizing Site Value | 07 Mar 2025 | 00:02:13 | |
When selling a clinical trial site, many owners focus solely on the amount they’ll receive, but the real key is understanding the multiplier that determines your valuation. In M&A transactions, hitting the right EBITDA threshold—such as $3M, $10M, or $25M—can significantly increase your multiplier, turning a 6X valuation into 10X or more. While some claim multipliers as high as 26X, the reality is more complex. Beyond valuation, choosing the right private equity partner is just as critical. Do they want a standalone site, or will you be part of a network? Will you need to align with new processes or teams? Is your payout immediate, or will some be deferred? Many sellers are caught off guard when the check they expected never arrives as planned. If you're considering an M&A transaction, don't just focus on the final price—understand the full process. We help clinical research sites navigate these deals strategically. Call, click, or email to learn more! www.kulkarnilawfirm.com | |||
| Trends in Small Life Sciences Transactions | 05 Nov 2025 | 00:12:46 | |
Darshan Kulkarni in conversation with Nella Bloom, for an in-depth discussion on the current state of small business transactions, private equity trends, and the challenges of advising clients in an unpredictable market. Nella, an experienced attorney specializing in mergers and acquisitions and fractional general counsel services, explains how today’s business climate feels increasingly unstable. Rapid regulatory changes, unpredictable government responses, and evolving funding structures have made it difficult for lawyers and entrepreneurs alike to plan ahead. From shifting SBA lending rules to changing tax and formation requirements, she notes that the uncertainty affects every stage of dealmaking and business operation. The conversation then turns to broader market trends. Nella has observed a rise in corporate bankruptcies, layoffs among highly skilled professionals, and a surge in individuals turning to entrepreneurship after losing traditional corporate jobs. Many of these professionals seek to launch consulting practices or small service-based companies, often entering a market filled with both opportunity and risk. Darshan and Nella explore how private equity (PE) firms are reshaping the business acquisition landscape. While PE investors focus on maximizing profit and achieving lucrative exits within three to five years, owner-operators often prioritize legacy, continuity, and mission. This misalignment, Nella explains, can lead to misunderstandings and unmet expectations. Despite the allure of quick financial gains, she cautions that many sellers underestimate the long-term implications of selling to private equity — from loss of control to cultural shifts in the organization. They also discuss why so many M&A deals underperform or fail to deliver on their projected synergies. Miscommunication between buyers and sellers, unrealistic valuations, and differing definitions of success often lead to disappointment or even litigation. Nella emphasizes the importance of understanding key contractual elements such as non-competes, earn-out clauses, and payment contingencies — and how they can become major pitfalls if not carefully negotiated. In one particularly insightful segment, Nella describes how non-compete agreements can unfairly bind small business owners, while private equity firms often face no reciprocal restrictions. She warns sellers to be vigilant and realistic about the legal and financial leverage they bring to the table. Darshan and Nella close the discussion by reflecting on the emotional side of these deals — the excitement of potential growth, the fear of loss, and the difficulty of maintaining balance when passion meets financial pressure. Both agree that while private equity brings valuable resources and structure, small business owners must enter negotiations with clear goals, legal protection, and a firm understanding of what success truly means for them. www.kulkarnilawfirm.com | |||
| 5 Key Areas to Review in Clinical Trial Agreements | 05 Mar 2025 | 00:03:33 | |
Contract issues are more common than you think. Edye Edens shares the five critical areas you should always review before signing:
A thorough review of these areas can prevent costly mistakes. Need expert guidance? Call us. www.kulkarnilawfirm.com | |||
| Discussing Stem Cell Research Opportunities with a Research Site Owner | 03 Mar 2025 | 00:07:43 | |
At the Site Council meeting, Darshan Kulkarni had the opportunity to speak with Mohamed Hakim, a site owner who has consolidated six clinical research sites into three. Their conversation explored the evolving landscape of clinical research, particularly in stem cell studies, in light of the regulatory shifts happening under the Trump administration. Mohamed highlighted the increasing number of clinical trials and the expansion of pharmaceutical research into Europe, creating new opportunities for site owners like himself. One of the most exciting developments he shared was his team’s work in stem cell research. They have been conducting investigator-initiated trials, including a recent study on concussions using stem cells. The study involved 20 participants—military personnel, football players, and soccer players, both male and female—who received IV injections of stem cells. The preliminary results were highly promising, demonstrating significant potential for using stem cells in neurological recovery. They also discussed the complex regulatory framework surrounding stem cell research. Stem cell therapies exist in a regulatory gray area, straddling the line between medical practice and drug development. The FDA has historically scrutinized stem cell treatments, particularly when manipulation is involved—such as freezing and thawing cells, which can push the therapy into the category of a drug requiring extensive clinical trials. Mohamed explained that his team is carefully navigating these challenges by ensuring compliance with FDA regulations. In California, they operate under strict guidelines, treating patients with same-day stem cell procedures to avoid regulatory pitfalls associated with long-term storage or modification. A key aspect of their approach is leveraging the “Right to Try” law, which allows patients who have exhausted other treatment options to access investigational therapies. Mohamed noted that this has been particularly relevant in their work on conditions like concussions and Alzheimer’s. While they are not aiming to reverse Alzheimer’s, their research focuses on delaying its progression. The discussion also touched on the commercialization of stem cell therapies. Some clinics, particularly in states like Texas, have bypassed the traditional FDA approval process by charging patients directly for experimental treatments. However, Mohamed and his team are committed to following proper research protocols and avoiding legal risks. They briefly operated a sub-site dedicated to stem cell treatments but shut it down after seeing the FDA crack down on similar operations in New York. Now, they are taking a cautious approach, waiting for regulatory clarity before expanding further. Mohamed’s journey into stem cell research was driven by his partnership with an orthopedic surgeon and a sports medicine doctor—who was also the team doctor for the Chargers. Their initial goal was to find effective treatments to help athletes recover faster. From there, they expanded their research into broader medical applications, including orthopedic and cardiovascular conditions. www.kulkarnilawfirm.com | |||
| Quality Management: A Must in Clinical Trial Contracts | 01 Mar 2025 | 00:06:23 | |
In the second part of our discussion, Edye Edens speaks with subject matter expert Helen Maurer about integrating quality management into clinical trial contracts. While contracts often cover legal aspects like termination and jurisdiction, they frequently lack clear quality management plans. Helen emphasizes the importance of defining responsibilities, risk levels, and monitoring expectations upfront to avoid confusion and compliance issues later. Key takeaways:
By embedding quality management into contracts and budgets, research teams can set clear expectations, improve compliance, and avoid costly surprises down the line. www.kulkarnilawfirm.com | |||
| AI-Powered Chatbots in Pharma Sales and Education | 27 Feb 2025 | 00:05:29 | |
ChatGPT's recent update introduced an AI engagement feature reminiscent of the movie Her, the conversation is highly relevant as AI becomes more integrated into daily business operations. While AI voice chat offers benefits like consistent messaging, 24/7 availability, and efficiency, it also brings significant risks—especially in the heavily regulated pharmaceutical and medical device sectors. The episode explores key challenges, starting with privacy and security concerns. AI-enabled systems handle large amounts of sensitive patient data, often governed by regulations like HIPAA in the U.S. and GDPR in Europe. Companies must ensure they have proper consent and compliance mechanisms in place to avoid major privacy breaches. Darshan also highlights risks related to the accuracy and reliability of AI responses. AI algorithms can misinterpret queries or provide outdated information, which could lead to serious legal and financial consequences. Compliance with regulatory standards is another major topic. AI systems must adhere to strict FDA, CMS, OIG, and DOJ guidelines, just like human representatives. Improper training or significant deviations by AI can be considered violations, leading to fines or even jail time. The ethical dimension is also discussed, emphasizing that while AI can mimic empathy, it lacks the emotional intelligence of human interactions, which could result in dissatisfaction or ethical concerns. We talk about the importance of managing these risks with well-established policies, robust training, regular auditing of AI systems, and a balance between AI and human interactions. He underscores the need for expert legal guidance in ensuring that AI systems are both compliant and secure. www.kulkarnilawfirm.com | |||
| Will New Tariffs Disrupt Your Next Pharma Deal? | 26 Feb 2025 | 00:01:21 | |
The proposed 25% tariff on pharmaceutical APIs from China could have far-reaching effects on M&A transactions within the life sciences and healthcare industries. Since a significant portion of pharmaceutical raw materials originate in China, companies may face increased costs not only in sourcing but also in sales, as Canada considers imposing its own tariffs. This could disrupt global supply chains, making due diligence even more critical for buyers evaluating international pharmaceutical and biotech companies. Traditionally, M&A analysis focuses on vendor agreements, but in light of these tariffs, companies must now assess the entire supply chain—including alternative sourcing options, regulatory approvals for suppliers, and potential delays in manufacturing. Some predict this will drive more companies to acquire U.S.-based API manufacturers to reduce dependency on foreign supply chains, especially if domestic tax incentives, such as potential Trump-era tax cuts, make U.S.-based production more attractive. If these factors align, the industry could see a shift toward reshoring pharmaceutical manufacturing and a surge in domestic M&A transactions as companies adapt to a changing trade landscape. www.kulkarnilawfirm.com | |||
| Protecting Patient Data in a Changing Regulatory Landscape | 25 Feb 2025 | 00:05:10 | |
In this discussion, Edye Edens and Helen Maurer dive into the critical topic of data privacy and security in clinical research, particularly in light of potential federal oversight. Helen, an expert in compliance and quality assurance within oncology research, emphasizes the need for clinical trial sites—especially those at major academic medical centers—to understand whether their privacy regulations fall under state or federal jurisdiction. They explore hypothetical scenarios where federal agencies or other entities might request access to clinical trial data, questioning the potential motivations behind such requests, including public health initiatives or policy changes. Edye and Helen stress the importance of ensuring that participant data remains protected, that any data-sharing aligns with consent agreements, and that institutions are prepared to navigate these complex regulatory challenges. Given the rapidly shifting legal landscape, they highlight the need for vigilance and proactive compliance strategies to safeguard sensitive healthcare data. www.kulkarnilawfirm.com | |||
| Off-Label Promotion Changes in 2025 | 24 Feb 2025 | 00:31:17 | |
Stephanie Trunk and Darshan Kulkarni discuss the evolving landscape of the pharmaceutical industry under the Trump Administration in 2025. They highlight the uncertainty surrounding regulatory changes, particularly with new leadership at the FDA, CMS, and HHS (with RFK confirmed). There is concern over shifting prosecutorial priorities, overturned FDA diversity initiatives, and potential scrutiny of diversity efforts in private companies. A major focus is the changing environment of off-label marketing, where reliance on FDA guidances is being replaced by stricter adherence to statutory regulations due to court rulings like Coronia and Loper Bright. This shift creates uncertainty for regulated industries, as enforcement becomes less predictable.
Off-Label Promotion & Enforcement:
Compounding & the GLP-1 Market:
Key Compliance Considerations:
The overall sentiment reflects industry uncertainty as pharmaceutical companies navigate regulatory and legal shifts in this new landscape. www.kulkarnilawfirm.com | |||
| Turning Physicians into Leaders | 21 Feb 2025 | 00:16:23 | |
Kate Woods interviews Lee Scheinbart, who shares valuable advice for physicians aspiring to become Chief Medical Officers (CMOs) or take on leadership roles in healthcare. Lee stresses the importance of being intentional in career decisions and encourages young physician leaders to first focus on becoming competent clinicians. He advises earning medical degrees, completing training, and gaining clinical experience for 5 to 10 years before transitioning into leadership. Lee also discusses the financial pitfalls physician leaders often face, particularly not recognizing their own value. He explains how clinical expertise can reduce waste and inefficiencies in healthcare organizations, bringing significant value beyond patient care. He also emphasizes the importance of collaboration between clinicians and non-clinical peers, advocating for mutual understanding and respect to strengthen healthcare teams. Additionally, Lee talks about his podcast "Fire Chief," which addresses disaster management and crisis leadership for CMOs. He shares his experiences in high-pressure situations like the COVID-19 pandemic and offers advice on managing stress, urging future leaders to stay proactive in maintaining their well-being. Lee concludes by encouraging aspiring leaders to focus on developing their leadership skills and find mentors to guide them in their career journey. www.kulkarnilawfirm.com | |||
| Key Regulatory Agencies in Pharma M&A | 20 Feb 2025 | 00:01:18 | |
When conducting an M&A transaction in the pharmaceutical or medical device industry, compliance must be a top priority. Regulatory agencies like the DOJ, FDA, OIG, and OCR have strengthened oversight, emphasizing successor liability and the need for strong compliance programs. Beyond FDA regulations, companies must consider fraud prevention, HIPAA, and evolving privacy laws at both federal and state levels. Ignoring these factors can lead to serious legal and financial consequences. Stay informed—compliance isn’t optional. www.kulkarnilawfirm.com | |||
| Does E6 (R3) Blur the Line Between GCP and Privacy Laws? | 19 Feb 2025 | 00:01:37 | |
In this video, Edye Edens discusses the recent transition of ICH GCP E6 from R2 to R3, highlighting an interesting question she received: Is R3 evolving into a privacy doctrine? Given its increased focus on data protection, system validation, and privacy responsibilities, some wonder if it overlaps with regulatory frameworks like HIPAA, especially as OCR proposes significant updates to the Security Rule. However, Edens notes that while R3 contains more references to privacy, it does not explicitly mention cybersecurity, which is a major focus of OCR’s changes. She argues that R3 is not attempting to replace or overshadow existing privacy regulations but rather aligns with their broader goals of data confidentiality and integrity. She invites discussion on whether others see any regulatory overlap. www.kulkarnilawfirm.com | |||
| Protect Your Site If a Sponsor Terminates Early | 03 Nov 2025 | 00:00:59 | |
When sponsors terminate a clinical trial early, research sites may face financial losses for preparatory or ongoing work. To mitigate this risk, contracts should explicitly guarantee payment for all work performed up to the termination date, as well as reimbursement for non-cancellable expenses such as IRB fees, recruitment advertising, and staff training. Including a wind-down clause ensures compensation for necessary closeout activities—such as patient chart reviews, final visits, and data queries. Sites may also consider negotiating a minimum payment guarantee if termination occurs within the first 6–12 months and requesting upfront payments to offset early-stage costs. These protections help ensure that early termination does not disrupt site operations or financial stability. www.kulkarnilawfirm.com | |||
| RFK Jr. Confirmed as HHS Secretary: What It Means for Healthcare Policy | 18 Feb 2025 | 00:08:01 | |
Edye Edens and Darshan Kulkarni dive into the confirmation of RFK Jr. as Secretary of Health and Human Services and the immediate impact of President Trump’s latest executive order. The order mandates a comprehensive national health assessment, addressing issues like obesity, diabetes, and pediatric disorders, and aims to reshape the country’s approach to preventive care. While the focus on public health challenges is timely, the broad and vague nature of the directive raises questions about its execution and potential consequences. A key concern is how the administration will interpret health data—whether it will rely on scientific evidence or lean into controversial theories, particularly regarding vaccines and chronic illnesses. RFK Jr.’s alignment with the "food as medicine" movement could bring renewed attention to nutrition and prevention, but there is also the risk of oversimplifying complex health issues. Will this shift in policy lead to meaningful improvements in healthcare access and disease prevention, or will it fuel misguided initiatives based on correlation rather than causation? Darshan and Edye explore the broader implications, including the potential for changes in clinical trial funding, regulatory oversight, and access to medications. They emphasize the need for a balanced approach that values scientific rigor while addressing public health challenges. With major policy shifts on the horizon, this is a developing issue that will demand close scrutiny in the weeks to come. Stay tuned as they continue to break down the impact of these decisions on healthcare, research, and patient outcomes. www.kulkarnilawfirm.com | |||
| America’s Research Future in Jeopardy | 15 Feb 2025 | 00:07:44 | |
Darshan Kulkarni and Edye Edens break down the significant impact of the Trump administration’s decision to cut NIH funding and reduce agency workforces, including the FDA, OHRP, and other key regulatory bodies. They discuss how these cuts could lead to serious disruptions in research funding, approval timelines, and the overall pace of medical innovation in the U.S. While some argue that such reductions could improve efficiency and reduce waste, others fear the immediate and long-term consequences—particularly for investigator-initiated trials, rare disease research, and the ability of institutions to remain globally competitive. The conversation highlights the potential ripple effects, including workforce layoffs, the shuttering of critical trials, and delays in drug approvals. With the FDA considered the gold standard in regulatory oversight, a drastic reduction in its capacity could have global repercussions, potentially undermining trust in the U.S. approval process. Moreover, the lack of transition planning and abrupt implementation raises concerns about whether the administration has fully considered the real-world impact of these cuts. Edye and Darshan also examine the broader economic and geopolitical implications, questioning whether these cuts align with the administration’s “America First” philosophy. They discuss how China and other countries are rapidly advancing in drug innovation, in part due to U.S.-led research. If domestic funding dries up, there is a risk that pharmaceutical and biotech breakthroughs could shift overseas, weakening America’s leadership in life sciences. Ultimately, they stress the need for informed decision-making, transparency, and better representation of key stakeholders in these high-stakes policy shifts. Without a strategic approach, the short-term cost-cutting measures could create long-term challenges, not only for researchers and institutions but also for patients who depend on groundbreaking medical advancements. www.kulkarnilawfirm.com | |||
| Trump Administration’s NIH cuts: Will they cripple US medical research? | 14 Feb 2025 | 00:07:48 | |
Darshan Kulkarni and Edye Edens discuss the recent controversy surrounding the Trump administration’s decision to cap NIH overhead funding (also known as indirect costs or F&A) at 15%. This sweeping change has already sparked significant backlash, with academic medical centers, particularly in Democratic states, filing lawsuits to challenge the policy. The cap threatens to disrupt funding structures that support essential research, potentially undermining the United States’ role as a global leader in medical innovation. They break down the impact of this decision, highlighting how research costs vary significantly based on location—conducting studies in Boston versus Oklahoma City, for example, involves vastly different expenses. A one-size-fits-all cap could have unintended consequences, particularly in an era where supply chain disruptions and rising costs are already straining research budgets. A major concern is how this will affect investigator-initiated and subsidized trials, which often operate at a loss but are crucial for rare diseases and specialized treatments. These trials provide hope to patients who might otherwise have no viable treatment options, and without adequate funding, such research could dwindle. The discussion also covers the broader legal and political landscape. The Association of American Medical Colleges (AAMC) has now filed a federal lawsuit seeking a nationwide temporary restraining order on enforcing the cap, marking a significant escalation in the legal battle. With past instances of the Trump administration disregarding court orders, Darshan and Edye explore the potential for a constitutional crisis if the executive branch ignores judicial rulings. Further, they examine the possible influence of private corporations on this policy shift. Many corporations that fund research typically limit their overhead contributions to around 15%, and some members of the administration have ties to these corporations. The hosts speculate that the policy may have been designed to align federal funding with corporate standards—potentially at the expense of public research institutions. Ultimately, they question whether these cuts truly support the administration’s “America First” philosophy. If the goal is to maintain U.S. dominance in scientific research, slashing funding without strategic adjustments could have the opposite effect, weakening the country’s ability to innovate and compete globally. With legal challenges underway and research institutions scrambling to adjust, this conversation is just the beginning of what promises to be a rapidly evolving and highly contentious issue. www.kulkarnilawfirm.com | |||
| DEI Under Trump: What It Means for Clinical Trials | 13 Feb 2025 | 00:07:47 | |
The Trump administration’s early actions have significantly impacted federally funded programs, particularly in the clinical trial space, by rolling back diversity, equity, and inclusion (DEI) initiatives. This shift raises serious concerns for scientific research, as diversity in clinical trials ensures that drugs and devices are effective across different populations. Historically, most approved treatments have been tested primarily on white males, creating gaps in data for other demographic groups. Despite the removal of DEI-related FDA guidance, clinical trial sponsors, sites, and institutions must consider broader legal and financial risks. The Department of Justice (DOJ) and other agencies are scrutinizing compliance, and organizations receiving federal funding could face funding cuts or legal action for perceived discrimination. Companies must carefully assess the regulatory landscape and determine their risk tolerance while ensuring their trials remain scientifically sound. Darshan Kulkarni and Edye Edens discuss the rapidly evolving situation, the potential risks for the clinical research industry, and what companies should do to navigate these shifting regulations. www.kulkarnilawfirm.com | |||
| CAPA & RCA: A Must for Pharma M&A | 12 Feb 2025 | 00:01:39 | |
When acquiring a pharmaceutical company, evaluating its quality and compliance programs is crucial. A strong program starts with well-documented policies and procedures, followed by comprehensive training to ensure employees understand and follow them. However, having policies in place isn’t enough—regulatory bodies like the FDA and DOJ stress that enforcement and documentation are essential. If an issue isn’t written down, it effectively never happened. No regulator expects perfection, but they do expect companies to investigate mistakes, determine their root causes, and take corrective and preventive actions (CAPAs) to ensure compliance issues don’t recur. A well-structured CAPA process demonstrates a company’s commitment to regulatory standards and operational excellence. Corrective actions address immediate issues, while preventive actions ensure systemic improvements. When evaluating a potential acquisition, look beyond vendor agreements and examine the entire supply chain. A company with a proactive compliance culture is less likely to face regulatory penalties and will provide greater long-term value. www.kulkarnilawfirm.com | |||
| Trump Targets Indirect Costs in NIH Funding | 11 Feb 2025 | 00:01:21 | |
On Friday, the Trump administration announced a 15% cap on NIH indirect costs, raising important questions about its impact on research funding. Edye Edens breaks down what this means, clarifying that while direct costs like salaries and equipment remain unchanged, the cap affects crucial behind-the-scenes expenses such as lab maintenance, IT infrastructure, cybersecurity, and compliance. Understanding these distinctions is key as institutions adapt—watch as Edye unpacks the details. www.kulkarnilawfirm.com | |||
| The USAID Halt and Its Consequences for Clinical Research | 10 Feb 2025 | 00:02:29 | |
The Trump administration’s actions have effectively halted USAID-funded clinical research worldwide, creating an unprecedented situation with significant ethical, legal, and medical implications. Clinical trials that relied on USAID funding have stopped, leaving ongoing research in limbo and raising serious concerns about what happens to trial participants and who bears responsibility for any resulting harm. Key Legal and Ethical Questions: 1. Who is the sponsor? If the U.S. government was the official sponsor of a trial, sovereign immunity could come into play. This legal doctrine generally protects governments from being sued unless they explicitly waive immunity. Whether the U.S. government would assert sovereign immunity in this situation remains unclear. 2. Can individuals be held responsible? Legal action against government officials, including former President Trump and members of his administration, would depend on whether they were acting in their official capacities. If they were, they may be shielded from personal liability. 3. What about pharmaceutical companies? If a trial was co-funded by multiple entities—such as the NIH, USAID, and a private pharmaceutical company—the company might still bear responsibility. The extent of its liability would depend on contractual agreements, funding structures, and trial oversight mechanisms. This situation is virtually without precedent, making it difficult to predict outcomes. However, if trial participants suffer harm due to halted research, legal action is almost certain. The coming months may bring lawsuits, debates over liability, and broader discussions about the role of government funding in global clinical research. www.kulkarnilawfirm.com | |||
| Ebola Vaccine Trial in Record Time! | 08 Feb 2025 | 00:02:29 | |
On January 30, 2025, Uganda confirmed an outbreak of the Ebola Sudan virus, and in an unprecedented global first, a clinical trial to assess the efficacy of a vaccine against the virus was launched within just four days. This rapid response was made possible by proactive planning following a 2022 outbreak, during which the Ugandan Ministry of Health, Makerere University, and the Uganda Virus Research Institute implemented a strategy to fast-track future trial activations. By pre-selecting investigators, securing protocol approvals, and ensuring regulatory readiness, they positioned themselves to immediately initiate the trial once a new outbreak emerged. With WHO’s support, this initiative represents a groundbreaking moment in clinical research—offering real-time data collection during an active outbreak while potentially saving countless lives. The WHO’s press release details the extensive collaboration and meticulous groundwork that made this possible, reinforcing the importance of preparedness in global health crises. www.kulkarnilawfirm.com | |||
| Your Clinical Trial Site M&A Agreement is Exposing You to Risk | 07 Feb 2025 | 00:00:50 | |
When working on an M&A transaction involving a clinical trial site, it's crucial to thoroughly review vendor agreements. It's not just about what is included, but what is missing. For example, do you have the right quality and privacy agreements in place, or are you unknowingly exposing yourself to liability? If there’s a lack of necessary agreements, it’s important to assess whether it’s due to ignorance or an oversight that could lead to future legal risks. If you're unsure, reach out to ensure you're on the right track and avoid unnecessary liabilities. www.kulkarnilawfirm.com | |||
| What Does ICH E6 R3 Say About Returning Data to Participants? | 05 Feb 2025 | 00:01:01 | |
The most recent ICH E6(R3) final guidance introduces critical updates to Good Clinical Practice (GCP), particularly around informed consent and participant data access. The guidance emphasizes greater flexibility and the use of technology-driven innovations to enhance how patients understand what they are consenting to. A significant update appears in section 2.8 (Investigator Responsibilities), which now requires a clear plan for returning trial-related data to participants when appropriate. This shift acknowledges the growing importance of transparency and participant rights in clinical trials. However, the guidance does not explicitly assign this responsibility to sponsors, despite them often being the ones who restrict access to participant data. While this change is a major step forward in ethical research practices, its practical enforcement remains uncertain without direct sponsor obligations. These updates reflect a broader shift toward patient-centric clinical trials, but questions remain about how effectively they will be implemented. www.kulkarnilawfirm.com | |||
| Are Pharma Chatbots Putting You at Regulatory Risk? | 01 Nov 2025 | 00:05:34 | |
Pharmaceutical chatbots are increasingly used to answer patient drug questions, but they carry significant regulatory and compliance risks. While the FDA has issued guidance on AI in drug development and medical devices, it does not yet provide a framework for patient-facing drug Q&A. That means chatbots that discuss side effects, dosing, or interactions exist in a gray zone, and any missteps could trigger FDA enforcement. The FTC enforces truth in advertising and consumer protection. Misleading claims, impersonating a doctor, or offering unverified information can lead to investigations. Some states, like Illinois, Nevada, Utah, and New York, are adding additional requirements such as licensed supervision or mandatory disclosures. The OIG and DOJ are also paying attention. If a chatbot steers patients toward off-label use that affects Medicare or federal healthcare claims, it could lead to fraud investigations. The DOJ’s new healthcare fraud task force has already targeted AI misuse in healthcare. Studies show chatbots provide inaccurate drug information 5–13% of the time, often with confidence, and sometimes at a reading level too high for many patients. These errors can misinform or even harm users, and regulators focus on outcomes, not intent. Best practices include disclosing that the chatbot is not medical advice, avoiding personalized dosing recommendations, auditing responses, implementing escalation paths to live healthcare professionals, and ensuring privacy and HIPAA compliance. With proper oversight, tools like Ceres can help document disclosures and escalation pathways, keeping innovation safe and compliant. www.kulkarnilawfirm.com | |||
| Navigating the Ongoing HHS Communication Freeze | 04 Feb 2025 | 00:02:28 | |
Now that we’ve passed February 1st, a key date for the potential easing of the freeze on all HHS communications, we find ourselves at February 3rd with no significant updates or changes. Despite expectations that restrictions might begin to lift, there has been no broad release of communications across federal agencies involved in clinical trials and regulatory oversight. While this does not provide definitive insight into the administration’s plans, it does confirm that, for now, the freeze remains in place. A critical concern emerging from this situation is the growing tendency of certain federal agencies to offer guidance on behalf of others. While this may be well-intentioned, it presents a risk for those in regulatory and research compliance. Some professionals are now uncertain about whether to report specific matters to Agency A, B, or C, given that the usual communication channels remain restricted. In some cases, agencies that are not the primary governing bodies for certain regulatory matters are advising stakeholders on reporting requirements, creating potential compliance pitfalls. It is essential to recognize that no directive has been issued allowing agencies to speak on behalf of one another. If an agency suggests a course of action based on its assumptions about another agency’s stance, this does not guarantee compliance. Any decision based on such unofficial guidance could lead to regulatory missteps. In light of this uncertainty, professionals should exercise extreme caution. For any matters related to patient safety or immediate harm, necessary clinical actions should be taken without hesitation, with follow-up reporting to the appropriate governing body as soon as possible. However, for proactive regulatory filings or compliance-related decisions that do not require urgent action, it may be prudent to wait for official guidance once communication channels reopen. As the situation develops, we encourage industry professionals to stay informed and connected. Continue monitoring updates from KLF for the latest insights and recommendations on navigating regulatory challenges during this period of restricted federal communication. If you have specific concerns, feel free to reach out for further guidance. www.kulkarnilawfirm.com | |||
| Ordinary People Are Changing Medicine | 03 Feb 2025 | 00:03:47 | |
Citizen biohacking is an empowering movement where individuals take medical innovation into their own hands, often stepping in when traditional medicine falls short. Driven by necessity, love, and a desire for survival, many have solved complex medical problems themselves, leading to groundbreaking discoveries. This trend raises important questions about safety, ethics, and the future of healthcare, with both promise and complexity. One of the most well-known examples is Lorenzo’s Oil, where Michaela and Augusto Odone developed a treatment for their son Lorenzo, who was diagnosed with a rare and fatal genetic disorder. Their research and persistence led to a groundbreaking treatment that helped slow the disease's progression. Another inspiring story is that of Dr. David Fajgenbaum, who, after being diagnosed with Castleman’s disease, repurposed existing drugs to stabilize his condition, saving his life and offering hope to others. These remarkable examples demonstrate how determination and innovation can lead to life-saving breakthroughs. However, citizen biohacking raises crucial concerns, such as safety and ethics. Operating outside the traditional medical system, it challenges regulatory bodies to reconsider how innovation is validated and tested. Despite these challenges, citizen biohacking is changing the landscape of medicine, pushing the medical community to think differently, adapt more quickly, and collaborate with unconventional innovators. If you’re interested in exploring these stories and the legal implications of this trend, tune in to our Darshan Talks podcast or reach out to Kulkarni Law Firm for expert guidance. www.kulkarnilawfirm.com | |||
| Trump’s First 10 Days: The Impact on Clinical Trials | 31 Jan 2025 | 00:02:29 | |
Edye Edens discusses how the first nine to ten days under the new administration have brought notable shifts for both healthcare and clinical research, particularly in regulatory compliance and funding. While remaining politically neutral, the focus is on understanding how these changes impact clinical trials and research oversight. A key update is that the federal communication freeze across health agencies is expected to ease by February 1, which should provide more clarity on the administration’s direction. However, concerns have emerged regarding a significant halt in NIH funding, disruptions in scheduled meetings for ongoing and proposed trials for 2025, and the removal of publicly posted regulations related to diversity initiatives. While some argue these policies were not strongly enforced previously, their sudden absence raises uncertainty about future regulatory actions. On a positive note, research that had been previously approved and grandfathered in is allowed to continue despite the communication freeze. At KLF, we are closely monitoring these developments, analyzing the latest updates, and advising our clients on navigating these evolving challenges. While uncertainty remains, no news is not necessarily bad news, and we are committed to keeping our clients informed and compliant. www.kulkarnilawfirm.com | |||
| Selling a Business with Issues | 31 Jan 2025 | 00:00:58 | |
When selling a company, certain issues may arise that could concern potential buyers. Here's a breakdown of how to approach them:
If you're navigating this process, getting the right advice is essential. Reach out to us for guidance on how to handle these complexities. www.kulkarnilawfirm.com | |||
| Breaking Down GCP E6(R3) | 28 Jan 2025 | 00:11:44 | |
Darshan Kulkarni and Edye Edens discuss the latest update to Good Clinical Practice (GCP) guidelines, E6 R3, was explored. GCP, developed by the International Council for Harmonisation (ICH), provides globally accepted ethical and operational standards for conducting clinical trials. The 2025 update represents a significant revision since its last update in 2016, emphasizing technology, data integrity, and structural changes to accommodate rapid innovation in clinical research. Key Highlights of E6 R3:
Implications for Stakeholders:
This update underscores the importance of staying informed about evolving guidelines to ensure compliance, safeguard participant rights, and maintain trial integrity. Stay tuned for more insights and discussions on navigating these changes effectively. www.kulkarnilawfirm.com | |||
| AdvaMed 7 rules for Essential AI Innovation | 25 Jan 2025 | 00:05:54 | |
Artificial intelligence (AI) is rapidly reshaping healthcare, with over 950 FDA-authorized AI devices transforming diagnosis, treatment, and administrative workflows. AdvaMed's new position paper emphasizes seven foundational principles to guide AI in medical technology development and regulation.
AI is a transformative force, but its integration into healthcare requires navigating complex regulatory, ethical, and operational challenges. At the Kulkarni Law Firm, we help companies align with these evolving standards, from FDA submissions to post-market obligations. What do you see as the biggest challenge for AI in healthcare? Share your thoughts below! For more insights, subscribe to the Darshan Talks Podcast or visit Kulkarni Law Firm for resources and consultations. www.kulkarnilawfirm.com | |||
| Teva’s Case Should Shape Your Pharma Strategy | 22 Jan 2025 | 00:01:21 | |
Teva Pharmaceutical's $450 million settlement highlights the challenges of compliance in the pharmaceutical industry. The Department of Justice accused Teva of violating the anti-kickback statute and the False Claims Act by using co-payment assistance programs to steer Medicare payments for its drug Copaxone while raising prices. Additionally, Teva admitted to price-fixing schemes for generic drugs like pravastatin. This case serves as a stark reminder that compliance isn't just about avoiding penalties—it's about building trust with patients, healthcare providers, and regulators. The key question for companies is: how robust is your compliance program? Are you ready for federal and state scrutiny? If you’re navigating these complexities, the Kulkarni Law Firm is here to help ensure your operations remain compliant and ethical. Reach out before small issues turn into costly legal battles. www.kulkarnilawfirm.com | |||
| AI’s Impact on Healthcare: Liability, Ethics, and Responsibility | 21 Jan 2025 | 00:08:10 | |
Today, we explore a pressing issue in the healthcare landscape: the liability associated with artificial intelligence (AI). As AI technologies transform healthcare—from diagnostic tools to treatment recommendations—it's crucial to understand the legal and ethical implications surrounding their use, particularly regarding accountability. AI systems can analyze vast amounts of data, providing insights that aid in diagnosing diseases and personalizing treatment plans. However, this advancement raises significant questions about liability: who is responsible if an AI system makes an error? The podcast argues that the responsibility should remain with healthcare providers, including physicians and nurses, as they are ultimately accountable for patient care. While AI can enhance decision-making, it lacks the human touch needed to navigate individual patient nuances. Providers must apply their clinical judgment to interpret AI-generated data and make informed decisions based on a comprehensive understanding of their patients. The Colorado Senate Bill, known as the Artificial Intelligence Act, reinforces the importance of maintaining healthcare provider accountability in AI usage. The legislation stipulates that providers cannot solely rely on AI for clinical decisions, ensuring that they use their professional judgment to evaluate AI data appropriately. This legal framework is critical for sustaining patient safety and trust within the healthcare system. The American Medical Association (AMA) supports this view, emphasizing that AI should enhance, not replace, human expertise in patient care. We also address the implications of AI's integration into healthcare. For AI to be effectively utilized, healthcare providers need proper training to understand the capabilities and limitations of AI systems. This includes training to critically evaluate AI-generated data, identify potential biases, and recognize when AI recommendations may not align with individual patient needs. Collaboration between AI developers and healthcare providers is essential in creating effective, reliable tools that serve diverse patient populations equitably. In conclusion, the podcast raises thought-provoking questions about the future of AI in healthcare. Should liability remain with AI providers, or does accountability rest more closely with the healthcare professionals who interpret and act on AI recommendations? As we continue to navigate this evolving landscape, understanding these issues will be vital for ensuring patient safety and trust in the healthcare system. Tune in for an insightful discussion on these critical topics! www.kulkarnilawfirm.com | |||
| Four Types of Research related Grant Fraud | 18 Jan 2025 | 00:04:56 | |
Grant fraud encompasses four critical issues that can have severe repercussions for institutions and individuals.
2. Misrepresenting Data for Funding:
3. Misrepresenting Data Arising from Grants:
4. Misuse of Grant Funds:
Grant fraud isn’t just unethical—it attracts significant scrutiny from federal agencies like the DOJ and the Office of Research Integrity. Ensuring compliance is vital to avoid legal, financial, and reputational damage. www.kulkarnilawfirm.com | |||
| Defining Scope in Due Diligence Transactions | 17 Jan 2025 | 00:00:53 | |
When conducting due diligence for a life sciences company, it's essential to align the scope with the transaction's objectives. Key considerations include:
Tailoring the due diligence process to these factors ensures a comprehensive evaluation, balancing thoroughness with cost-effectiveness. For more detailed guidance, reach out to us. www.kulkarnilawfirm.com | |||
| Are Your Cosmetic Company Records Ready for FDA Audits? | 30 Oct 2025 | 00:01:08 | |
Companies must maintain thorough records to meet FDA inspection requirements, including safety substantiation files, labeling proofs, ingredient documentation, and adverse event logs. Adverse event logs must be retained for six years (three for small businesses), while registration and product listing records require annual updates. Organized, accessible, and up-to-date records are essential not only for compliance but also for growth, due diligence, and investor confidence. Compliance is a strategic asset: clean, well-maintained files position a company as scalable and acquisition-ready, turning regulatory diligence into a competitive advantage. www.kulkarnilawfirm.com | |||
| Clinical Trial Checklist | 16 Jan 2025 | 00:07:33 | |
Darshan Kulkarni and Edye Edens discuss the essential steps for launching a clinical trial site, emphasizing the importance of navigating both state-specific regulations and the logistics involved. They begin by highlighting the critical role of informed consent and legal authority, which vary across states. In particular, states like Texas and California have stringent regulations that can impact how clinical research organizations are structured, especially regarding ownership and the corporate practice of medicine. The discussion also touches on the integration of telemedicine in decentralized clinical trials. While virtual visits offer convenience, Darshan and Edye stress the legal complexities, such as complying with state telehealth laws, particularly in therapeutic areas like behavioral health and psychiatry. They also point out that clinical research insurance policies may differ from standard medical practice insurance and could exclude research activities, so it’s important to confirm coverage. The conversation then moves to the qualifications and licensure of staff involved in clinical research. Different states have varying laws about what licensed professionals can engage in research-related activities, making it essential to understand local requirements. With the rise of artificial intelligence, Kulkarni and Edens explore its role in clinical trials, particularly AI tools like scribing, and the potential legal implications of using AI in clinical settings, including compliance with HIPAA. Finally, Darshan and Edye emphasize the need for a detailed, step-by-step plan to ensure both business and regulatory compliance. They stress the importance of preparing a comprehensive checklist that includes all necessary consents, privacy protocols, and regulatory assessments before engaging with patients and sponsors. This thorough approach ensures that your clinical trial site is properly structured, legally compliant, and positioned for success from day one. www.kulkarnilawfirm.com | |||
| Presidential Changes and Impact on Drug Related Misinformation | 14 Jan 2025 | 00:11:28 | |
Misinformation around vaccines and treatments isn’t new, but with figures like Robert F. Kennedy Jr. in the spotlight, how should regulatory agencies respond? There will be potential changes coming to the FDA and public health regulations with the new administration. Historical transitions, such as the one from the Obama administration to the Trump administration, will shape policy going forward, particularly in terms of regulatory priorities. The government will need to combat misinformation, and address potentially harmful claims without overstepping their bounds. This may include regulating off-label drug use and its efforts to prevent the misuse of certain medications, like ivermectin, especially during times of widespread misinformation. The FDA must strike a balance between providing accurate, science-backed information and respecting First Amendment rights, and whether the agency is doing enough to educate the public without infringing on free speech. Finally, the FDA will itself need to adapt. Some believe the FDA has been too lenient in some areas, this could be a time of significant change, while others may be concerned that the agency’s ability to safeguard public health could be compromised. Tune in to this engaging discussion between Dale Cooke and myself for a deeper look at how the regulatory landscape might evolve in the coming years. www.kulkarnilawfirm.com | |||
| Prep for Selling Your Company! | 12 Jan 2025 | 00:04:10 | |
When preparing to sell your pharmaceutical company, particularly with a Phase 1 product, it’s essential to assess potential buyers and ensure readiness. Darshan’s Insights:
2. Cultural and Operational Fit:
3. Investment Philosophy Alignment: When choosing a buyer, ensure their investment philosophy aligns with your business goals. For example, private equity (PE) firms may focus on operational efficiencies and scaling, while venture capital (VC) firms often prioritize innovation and growth potential. Understanding whether the buyer values your product pipeline, market strategy, or long-term vision will help determine if they are the right fit. This alignment is crucial to fostering a successful partnership post-sale. Edye’s Insights: 2. Contractual Obligations: 3. Compliance and Data Integrity: Final Thoughts: www.kulkarnilawfirm.com | |||